References
- Negri E, la Vecchia C, De Carli A. Cancer mortality in Italy, 1998. Tumori 2002;88:89-94
- Micheli A, Mugno E, Krogh V, Capocaccia Ret; EUROPREVAL Working Group. Cancer prevalence in European registries areas. Ann Oncol 2002;13:840-65
- Portenoy RK, Hagen NA. Breakth3rough pain: definition, prevalence and characteristics. Pain 1990;41:273-81
- Zeppetella G, Ribeiro MD. Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother 2003;4:493-502
- Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000;20:87-92
- Gomez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002;24:45-52
- Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34
- Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002;46:759-70
- Fortner BV, Okon TA, Ashlet J, et al. The zero acceptance of pain (ZAP) quality improvement project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. J Pain Symptom Manage 2003;25:334-43
- Song Y, Wang Y, Thakur R, et al. Mucosal drug delivery: membranes, methodologies, and applications. Crit Rev Ther Drug Carrier Syst 2004;21:195-256
- Popper L, Nolte T, Kaczmarek Z, et al. Intranasal fentanyl for relief of breakthrough pain in patients with cancer. Poster presentation at the 12th World Congress on Pain; 17-22 August 2008; Glasgow, Scotland
- Kress HG, Orońska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanil spray 50 to 200 μg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009;31:1177-91
- Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009;25:2805-15
- Agenzia Italiana del Farmaco. http://farmaco.agenziafarmaco.it/index.php
- Ricognizione e primo aggiornamento delle tariffe massime per la remunerazione delle prestazioni sanitarie. Gazzetta Ufficiale n. 289 del 13 dicembre 2006
- Ministero della Salute. Programmazione Sanitaria e Qualità leggi e documenti-Tariffario in euro delle prestazioni specialistiche, delle protesi e drg. www.ministerosalute.it/programmazione/normativa/sezNormativa
- Ruggeri M., Dibidino R., Cicchetti A. La stima dei pesi della qualità di vita basati sul modello EQ-5D. I risultati di uno studio pilota condotto su una popolazione italiana. Working paper
- Vissers DCJ, Malin L, Tolley K, et al. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value in Health 14 2011;27:4-281
- Frei A, Andersen S, Hole P, Jensen NH. A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain. J Pain Palliat Care Pharmacother 2003;17(2):5-26
- Kuo KL, Saokaew S, Stenehjem DD. The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother 2013;27(2):167-75
- Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002;3(1):38-44
- Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat Med 2001;15(4):323-8